Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3047461 A
Publication typeGrant
Publication dateJul 31, 1962
Filing dateJun 10, 1960
Priority dateJun 10, 1960
Publication numberUS 3047461 A, US 3047461A, US-A-3047461, US3047461 A, US3047461A
InventorsHardy Jr Robert A, Howell Charles F, Quinones Nicanor Q
Original AssigneeAmerican Cyanamid Co
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Central nervous system stimulant
US 3047461 A
Images(2)
Previous page
Next page
Description  (OCR text may contain errors)

rates This invention relates to a pharmaceutical composition and more particularly is concerned with a novel pharmaceutical composition having a stimulating effect on the central nervous system.

The present invention comprises a pharmaceutical composition containing as the active central nervous system stimulant -phenyl-2-methylimino-4-oxazolidinone which may be represented by the following general formula:

@amao O NH iron; (1)

Due to the mobility of the hydrogen atom it is quite likely that this compound may also exist in several additional tautomeric forms, one of which is shown:

I THCHa rr) It is to be understood that the present invention includes within its scope the above compound in all such tautomeric forms. For ease of description, however, the

compound herein is named as 5-phenyl-2-methylimino-4- oxazolidinone which is descriptive of the tautomeric form in which it is usually named and written.

S-phenyl 2 methylimino-4 oxazolidinone has been found to be a highly useful central nervous system stimulant. It shows a mild stimulant action and excellent anorexic action over a wide range of doses and possesses distinct advantages over other stimulant drugs such as the amphetamines and pipradrol.

Amphetamine and closely related compounds such as methamphetamine have been used as central nervous system stimulants for many years, but numerous undesirable side reactions accompany their administration. For instance, they cause more or less pronounced rise in blood pressure and there is a tendency toward developing tolerance upon continual use. The herein-described compound does not have these serious side-efiects and thus is markedly superior to the amphetamines. The compound of this invention is also, even at high doses, free from the undesirable adrenergic and cardiovascular actions characteristic of the amphetamines. As increasing doses of the amphetamines are given, convulsions are usually observed. The compound of this invention does not cause convulsions as the doses are increased. The compound possesses a low order of toxicity and a desirable spread between eifective and lethal doses; i.e.,

.a safe therapeutic index. The compound has a greater margin of safety than"pipradrol which shows a rather narrow range between effective and toxic doses. Furthermore, the compoundis more active than 5-phenyl-2- imino-4-oxazolidinone described in United States Patent No, 2,892,753. It is approximately 3.3 times as effective in causing a 50% increase in motor activity at a nontoxic .dose. This type of test is well recognized as a useful method for the' determination of stimulant activity and is described by P. B. Dews, British Journal of Pharice macology, vol. 8, page 46 (1953), and by G. Chen et al., Journal of Pharmacology and Experimental Therapeutics, vol. 127, page 241 (1959).

5-phenyl-2-methylimino-4-oxazolidinone is a white, crystalline solid, only slightly soluble in water. basic substance, soluble in aqueous mineral acids at room temperature, and in some cases forms an insoluble acid addition salt. It also dissolves in alkaline solutions.

The active compound may be used in the form of the free base or as a non-toxic acid addition salt such as the hydrochloride, sulfate, phosphate, citrate, etc. The active compound may be administered orally or parenterally and when so administered is a central nervous system stimulant at individual doses ranging from about 1 to 100 milligrams. The dosage regimen can be adjusted to provide the optimum therapeutic response. For example, several doses may be administered daily, or the dose may be proportionately reduced as indicated by the exigencies of the therapeutic situation.

For therapeutic administration this active compound may be incorporated with pharmaceutical excipients and used, for instance, in the form of tablets, dragees, capsules, suppositories, liquids to be administered in drops, emulsions, suspensions, syrups, chocolate, candy, chewing gum, and the like. Such compositions and preparations should contain at least 0.1% of the active ingredient. The percentage in the compositions and preparations may, of course, be varied and may conveniently be between about 2% and about 60% or more of the weight of the unit. The amount of active ingredient in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared in such a manner that a dosage unit form contains between about 1 and 100 milligrams of this compound.

Tablets, pills, dragees, and the like usually contain the following: A binder such as gum tragacanth, acacia, corn starch, or gelatin. A disintegrating agent such as corn starch, potato starch, alginic acid, or the like. A lubricant such as stearic acid, magnesium stearate, talc or the like. A sweetening agent such as sucaryl or saccharin may be added, as well as a flavoring such as peppermint, oil of Wintergreen, or cherry flavoring.

The compound may be prepared by the direct alkylation reaction illustrated by the following equation:

alkylating 0 NH agent J) 1 711 \O/ CHs-Y C [I (about 1 equiv.) N NE N rivatives, separation of the desired product in significant It is a" 3 EXAMPLE 1 -Phenyl-2-M ethylimino-4-0xazolidin0ne To a solution of sodium methoxide prepared by dissolving 12.6 grams of sodium in 500 milliliters of absolute methanol is added 88 grams of 5-pheny1-2-imino-4- oxazolidinone followed by the addition of 51 milliliters of dimethyl sulfate during minutes. The solution is heated at the refluxing temperature about 2 hours and cooled. The mixture is filtered, and some unreacted starting material is collected as the insoluble fraction. The filtrate is concentrated to a thick mass of crystals, and this mixture is dissolved in 500 milliliters of 1 normal sodium hydroxide. It is then extracted with 250 and 100 milliliter portions of methylene chloride, successively. The aqueous layer, containing the desired product, is then acidified with glacial acetic acid, cooled and filtered. The solid obtained is Washed with water and suspended in 550 milliliters of boiling methylene chloride and filtered to remove more unreacted starting material. The methylene chloride solution is dried over sodium sulfate, filtered and concentrated to give crude 5-phenyl-2- methylimino-4-oxazolidinone which is collected by filtration. After two recrystallizations from ethyl acetate, the product melts at 12l-124 C. The crude product may also be purified by partition chromatography on a celite column.

EXAMPLE 2 For 10,000 Tabletsg.

Active ingredient: 5 phenyl 2 methylimlno-inxavnlidinnne Lactose Corn Starch (For mix) Corn Starch (For paste) Magnesium Steal-ate (1%) The active ingredient, lactose and corn starch (for mix) are blended together. The corn starch (for paste) is suspended in 800 milliliters of water and heated with stirring to form a paste. This paste is then used to gr-anulate the mixed powders. Additional water is used, if necessary. The wet granules are passed through a #8 hand screen and dried at 120 F. The dry granules are then passed through a #16 screen. The mixture is lubricated with 1% magnesium stearate and compressed into tablets in a suitable tableting machine.

We claim:

1. A composition having a stimulating effect upon the central nervous system comprising as the essential active ingredient between about 1 and about 100 milligrams per dosage unit of 5-phenyl-2-methylimino-4-oxazolidinone and a pharmaceutical carrier.

2. A process of stimulating the central nervous system a of mammals which comprises administering a composi- This paste is then used to tion to mammals comprising as the essential active ingredient 5-phenyl-2-methylimino-4-oxazolidinone and a pharmaceutical carrier.

3. A process of stimulating the central nervous system of mammals which comprises administering a composition to mammals containing between about 1 and about milligrams of 5-phenyl-2-methylimino-4-oxazolidinone per dosage unit and a pharmaceutical carrier therefor.

Lienert et al: Chem. Abstracts, vol. 51, col. 15805 (1957).

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2892753 *Feb 26, 1957Jun 30, 1959Boehringer Sohn IngelheimCentral nervous system stimulant
US2943092 *Apr 23, 1957Jun 28, 1960Beranek JiriMethod of preparing 4-amino-3-isoxazolidinones
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3232945 *Aug 13, 1962Feb 1, 1966S E Massengill Company7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines
US3344155 *Dec 1, 1961Sep 26, 1967Hoechst AgHalogenated 8, 8, 8-triphenylpropylamine compounds
US3609159 *Jul 21, 1967Sep 28, 1971Dausse Lab5-phenyl-2-cyclopropylamino-4-oxazolinone, and process for making the same
US6290985Jan 11, 2001Sep 18, 2001Wm. Wrigley, Jr. CompanyBy chewing the gum, the medicament or agent is released from the product.
US6322806Jul 18, 2000Nov 27, 2001Wm. Wrigley Jr. CompanyOver-coated chewing gum formulations including tableted center
US6355265Feb 23, 2000Mar 12, 2002Wm. Wrigley Jr. CompanyOver-coated chewing gum formulations
US6444241Aug 30, 2000Sep 3, 2002Wm. Wrigley Jr. CompanyCaffeine coated chewing gum product and process of making
US6465003Aug 8, 2001Oct 15, 2002Wm. Wrigley Jr. CompanyDrug delivery
US6531114Nov 16, 2000Mar 11, 2003Wm. Wrigley Jr. CompanySildenafil citrate chewing gum formulations and methods of using the same
US6541048Dec 22, 2000Apr 1, 2003Wm. Wrigley Jr. CompanyCoated chewing gum products containing an acid blocker and process of preparing
US6558692Jan 11, 2001May 6, 2003Wm. Wrigley Jr. CompanyOver-coated chewing gum formulations
US6569472Sep 1, 2000May 27, 2003Wm. Wrigley Jr. CompanyCoated chewing gum products containing antacid and method of making
US6572900Jun 9, 2000Jun 3, 2003Wm. Wrigley, Jr. CompanyMethod for making coated chewing gum products including a high-intensity sweetener
US6579545Dec 22, 2000Jun 17, 2003Wm. Wrigley Jr. CompanyProviding chewing gum cores; providing a coating syrup comprising a bulk sweetener; providing antigas agent; applying antigas agent and coating syrup to cores and drying syrup to produce a coating on cores, coating containing antigas agent
US6586023Apr 19, 2000Jul 1, 2003Wm. Wrigley Jr. CompanyActive ingredient added to the chewing gum has been treated to control its rate of release from chewing gum by adding the treated active agent to a gum coating
US6592850Sep 19, 2001Jul 15, 2003Wm. Wrigley Jr. CompanySildenafil citrate chewing gum formulations and methods of using the same
US6627234Jul 21, 2000Sep 30, 2003Wm. Wrigley Jr. CompanyMethod of producing active agent coated chewing gum products
US6645535Dec 22, 2000Nov 11, 2003Wm. Wrigley Jr. CompanyMethod of making coated chewing gum products containing various antacids
US6663849Sep 1, 2000Dec 16, 2003Wm. Wrigley Jr. CompanyAntacid chewing gum products coated with high viscosity materials
US6773716Nov 13, 2001Aug 10, 2004Wm. Wrigley Jr. CompanyOver-coated chewing gum formulations
US6949264Jul 21, 2000Sep 27, 2005Wm. Wrigley Jr. CompanyNutraceuticals or nutritional supplements and method of making
US7115288Jun 3, 2003Oct 3, 2006Wm. Wrigley Jr. CompanyApplying first and second coating syrups to the cores and drying the syrups; antacid is also added; stabilizing the high intensity sweetener from degrading, by heating the two syrup coatings separately at different temperature, separating aldehyde flavor from sweetener layer; food processing
US7163705Dec 17, 2001Jan 16, 2007Wm. Wrigley Jr. CompanyChewing gums core with coating; drug delivery
US7622492 *Aug 18, 2006Nov 24, 2009Hoffmann-La Roche Inc.antidiabetic agents; (4S,7R)-1-Benzyl-7,8,8-trimethyl-2-phenyl-1,2,4,5,6,7-hexahydro-4,7-methano-indazol-3-one; treating metabolic disorder comprises diabetes, obesity or metabolic syndrome, type II diabetes
US7935362Nov 9, 2005May 3, 2011Wm. Wrigley Jr. CompanyOver-coated product including consumable center and medicament
US8679522Mar 20, 2008Mar 25, 2014Jack BarrecaChewing gum
Classifications
U.S. Classification514/376, 548/225, 424/48
International ClassificationA61K31/00
Cooperative ClassificationA61K31/00
European ClassificationA61K31/00